Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference

BEDMINSTER, N.J., July 7, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12th Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA.

Raphael J. Mannino, Ph.D., Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School, and a member of the Matinas BioPharma Scientific Advisory Board, will present on Friday, July 10, 2015, at noon during the "Trends in Anti-Infectives Marketplace" session.

Dr. Mannino's presentation entitled, "Novel Technology to Combat Drug-Resistant Infections," will focus on the significant worldwide health threat posed by rapidly spreading drug-resistant fungal and bacterial strains. During this presentation, he will discuss the Company's focus on developing lipid-crystal nano-particle cochleate formulations of approved highly potent, but very toxic, anti-fungal and anti-bacterial medications to provide new solutions for physicians to combat increasing drug-resistance.

Matinas BioPharma's proprietary cochleate formulation platform technology has three main benefits: (i) the solid, highly stable, lipid-crystal particle shields sensitive organs from toxic effects of anti-fungal and anti-bacterial drugs, (ii) it uses the body's natural defense systems to target delivery to the site of infection or inflammation, and (iii) it permits oral administration of currently injectable-only medications.

Pre-clinical animal studies with several anti-infective medications in cochleate formulations have demonstrated the promise and value of the Company's technology, resulting in collaborations with the National Institutes of Health/National Institute of Allergy and Infectious Disease ("NIH/NIAID"), which will initiate later stage clinical trials this year with this technology. With the broad applicability of the cochleate drug delivery platform and pre-clinical data across many therapeutic areas, including antivirals, vaccines and anti-inflammatories, Matinas BioPharma believes there are many medications already approved and in development with significant toxicity which stand to benefit from its cochleate platform and an improved clinical profile.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: Media Contact: David Connolly LaVoieHealthScience Phone: +1 (617) 374-8800 Email:

Source:Matinas BioPharma Holdings, Inc.